Cryosa, a medical device startup developing therapies for obstructive sleep apnea (OSA), announced Thursday it raised $21.5 million in a Series B funding found.

The Arden Hills-based company is working on a minimally invasive therapy for OSA that doesn’t require daily patient compliance.

The round was led by Chattanooga, Tennessee-based Solas BioVentures, with additional funding from Santé Ventures and Tokyo-based HOYA Corp.

Cryosa said it will use the funding to continue its human clinical trials.

“With the momentum of this funding round, we’re in a strong position to expand into our next phase of safety and efficacy clinical trials,” said Mark Christopherson, Cryosa president and CEO.

Get the full story at